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ABSTRACT  
 
Neuroprostanes are lipid mediators produced by non-enzymatic free radical peroxidation of 
docosahexaenoic acid (DHA). It is associated to a lower atherosclerosis risk suggesting a 
beneficial role in cardiovascular diseases. The aim of this study was to investigate the 
influence of DHA peroxidation on its potentially anti-arrhythmic properties (AAP) in 
isolated ventricular cardiomyocytes and in vivo in post-myocardial infarcted (PMI) mice. 
Calcium imaging and biochemical experiments indicate that cardiac arrhythmias induced by 
isoproterenol are associated with Ca2+ leak from the sarcoplasmic reticulum (SR) following 
oxidation and phosphorylation of the type 2 ryanodine receptor (RyR2) leading to 
dissociation of the FKBP12.6/RyR2 complex. Both oxidized DHA and 4(RS)-4-F4t-NeuroP 
prevented cellular arrhythmias and posttranslational modifications of the RyR2 leading to a  
stabilized FKBP12.6/RyR2 complex. DHA per se did no have AAP. The AAP of 4(RS)-4-
F4t-NeuroP was also observed in vivo. 
In this study, we challenged the paradigm that spontaneously formed oxygenated metabolites 
of lipids are undesirable as they are unconditionally toxic. This study reveals that the lipid 
mediator 4(RS)-4-F4t-neuroprostane derived from non-enzymatic peroxidation of 
docosahexaenoic acid, can counteract such deleterious effects through cardiac anti-
arrhythmic properties. 
Our findings demonstrate 4(RS)-4-F4t-NeuroP as a mediator of the cardioprotective AAP 
characteristics of DHA. This discovery opens new perspectives for products of non-
enzymatic oxidized omega-3 polyunsaturated fatty acids as potent mediators in diseases that 
involve ryanodine complex destabilization such as ischemic event. 
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INTRODUCTION 
 
The cardioprotective effects of omega-3 polyunsaturated fatty acids (3 PUFAs) have been 
evident since the mid-70s [1]. The intake of fatty fish such as mackerel or tuna is associated 
with a lower risk of cardiac arrhythmias including sudden cardiac death (SCD) [2–4] and 
arrhythmic coronary heart disease death [5]. Administration of Omacor®, a mixture of 850 
mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) the two major 
polyunsaturated fatty acids (PUFAs) of fatty fish, decreased the incidence of SCD in 
secondary prevention of myocardial infarction [6]. The mechanisms responsible for the anti-
arrhythmic properties (AAP) of PUFAs remain unclear. In dogs, infusion of a DHA emulsion 
tended to slow heart rate (HR), shortened the corrected QT interval (QTc) at rest and 
significantly prevented ischemia-induced fatal ventricular arrhythmias [7]. These 
experiments confirmed previous reports on the prevention of ischemia-induced ventricular 
arrhythmias in dogs [8] and marmosets [9] by PUFAs. In humans, a significant slowing of 
HR and the likelihood of prolonged QT has been observed [10]. 
Experimental studies on isolated cardiac cells suggest that 3 PUFAs have direct 
cardiac electrophysiological effects [11]. However, DHA is highly prone to peroxidation and 
we have shown that non-enzymatic oxygenated products of DHA and not DHA per se are 
active on cardiac ionic channels [12]. In agreement, it has been demonstrated in rabbit 
ventricular cells that early depolarization induced by H2O2 is inhibited by DHA while 
reactive oxygen species (ROS) production is not altered, indicating the resiliency of oxidized 
DHA [13].  
DHA can be oxidized through two pathways; enzymatically, resulting in the 
production of compounds such as resolvins or maresins, or non-enzymatically by ROS 
initiation and propagation of free radical reactions, leading to the release of numerous 
products, including neuroprostanes (F4-NeuroPs) [14]. Neuroprostanes are recognized as 
oxidative stress biomarkers for the DHA-rich brain and are associated to ischemic stroke and 
neurodegenerative diseases [15,16]. More recently, it has been proposed that F4-NeuroPs 
may play a favorable role as potential bioactive components in identifying atherosclerosis 
risk [17]. 
In the present study, we show through in cellulo and in vivo approaches that non-
enzymatic oxidation of DHA is a prerequisite to obtain ventricular anti-arrhythmic effects. In 
particular, one of the F4-NeuroPs isomer, 4(RS)-4-F4t-neuroprostane (4(RS)-4-F4t-NeuroP) 
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appears to be the main anti-arrhythmic metabolite of DHA in preventing deleterious post-
translational modification of RyR2 and thus regulating calcium homeostasis.  
 
 
MATERIALS AND METHODS 
 
Animal experiments  
Male C57Bl/6 mice (Janvier, France) of 7 weeks old were randomly assigned into two main 
groups 1) mice with post-myocardial infarction (PMI mice) after left coronary artery ligation 
as previously described [18] and 2) sham-operated mice that were submitted to the surgical 
procedure but not to the artery ligation. All animal-handling procedures conformed to 
European Parliament Directive 2010/63/EU and the institutional animal research committee 
council on the protection of animals (CEEA-LR-12096). 
In brief, anesthesia was performed for left thoracotomy and cardiac monitoring (2% 
isoflurane/O2, Aerrane®, Baxter, France). The artery was ligated 1-2 mm beyond the 
emergence from the top of the left atrium, using an 8-0 suture for PMI mice. A subcutaneous 
injection of 0.01 mL buprenorphine solution (0.3 mg/mL) for post-operative analgesia was 
administered. Shams were subjected to the same surgical procedure but without coronary 
artery ligation. The mice were housed in single cages in a room under regulated temperature 
and hygroscopic conditions (23±1°C, 45±10% humidity, light-dark schedule of 12h:12h ad 
libitum feed). 
After 4 weeks, the mice were randomly assigned to the different treatment groups: 
Sham and PMI dosed with vehicle (NaCl 0,9%); PMI mice treated with 10 µM DHA (PMI 
DHA); PMI treated with 10 µM DHA and 1 µM -tocopherol (PMI DHA + Vit E); PMI mice 
treated with 10 µM DHA and 1 µM hydrogen peroxide (PMI DHA + H2O2) and PMI mice 
treated with 1 µM 4(RS)-4-F4t-NeuroP. We chose to work on PMI mice challenged with NE 
since it has been shown that the AAP of DHA is secondary to myocardial infarction in human 
[6]. 
Treatments were administrated as intravenous injection (200 µl) of the prepared 
solution equivalent to 10 times the concentration to reach the final concentrations matching in 
cellulo experiments. 
It is known that the activation of the adrenergic nervous system is one factor that may 
play a crucial role in the genesis of arrhythmias associated with acute myocardial infarction 
[19]. To mimic this activation, all PMI mice were then intra-peritoneally (i.p.) challenged 
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with the 1-adrenergic agonist, norepinephrine (2.5 mg/kg) [20] 20 min after they received 
their treatment. 
 
Echocardiography  
Doppler echocardiography was performed using a high-resolution ultrasound system (Vevo 
2100; VisualSonics, Toronto, Canada) equipped with a 40-MHz transducer. The mice were 
anesthetized with 1.5% isoflurane in 100% oxygen and placed on a heating table in a supine 
position. Body temperature was monitored through a rectal thermometer to be maintained at 
36-38°C and electrocardiograms (ECG) were recorded all along the echocardiographic 
procedure with limb electrodes.  Ejection (EF%) and shortening (SF%) fractions were 
calculated from the left ventricular diameters on M-mode measurements at the level of 
papillary muscles in a parasternal short-axis two-dimensional view. To better consider 
coronary ligation-induced left ventricular remodeling, EF was also calculated from a B-mode 
parasternal long axis view (EF% B-mode) by tracing endocardial end-diastolic and end-
systolic areas to estimate left ventricular volumes, and the endocardial fractional area change 
(FAC%) on a parasternal short-axis view at papillary muscle level was calculated. Pulsed-
wave Doppler of the ascending aortic blood flow was recorded permitting measurements of 
the velocity time integral (AoVTI). All measurements were quantified and averaged for three 
cardiac cycles (Table 1).  
 
Synthesis of 4(RS)-4-F4t-NeuroP 
Using the protocol previously reported, we synthesized F4-NeuroPs. The strategy is based on 
an easily accessible bicyclic precursor to obtain isoprostanoid derivatives [21], while more 
refined strategy were used for the synthesis of the isomers, 4(RS)-4-F4t-NeuroP [22], 10-F4t-
NeuroP [23] and 14(RS)-14-F4t-NeuroP (non yet published). The 13-F4t-NeuroP was 
synthesized using another strategy [24].  
 
Fatty acid solution and oxidation  
To observe antioxidant or oxidant effect, cells were incubated 20 minutes in Tyrode solution 
containing in 10 µM DHA or 10 µM DHA + 1 µM Vit E or 10 µM DHA + 1 µM H2O2. To 
prepare these solutions, DHA (stock prepared in ethanol) was added in the Tyrode solution 
after Vit E (stock prepared in chloroform) or H2O2 (stock prepared in reverse osmosis water). 
Stock solution of 4(RS)-4-F4t-NeuroP was prepared in Tyrode solution and diluted 
accordingly for the experimentations. 
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Quantification of 4(RS)-4-F4t-NeuroP 
In Tyrode solution (control), 10 µM DHA was incubated with or without 1 µM α-tocopherol 
(Vit E) or 1 µM hydrogen peroxide (H2O2) for 20 min in room temperature. The reaction was 
terminated with antioxidant butylated hydroxytoluene BHT (0.005%, w/v). The internal 
standard C21-15-F2t-IsoP (2.5 ng), synthesized by IBMM (Montpellier, France) laboratory 
was added to each sample mix. The sample was further diluted in aqueous sodium acetate 
solution (pH 4.6), acidified with 1M HCl and applied to pre-washed (methanol) Bond Elut 
Certify II SPE cartridge (Agilent, CA USA). After loading the sample (control, DHA or 
DHA+VitE or DHA+H2O2), it was sequentially cleaned with water/methanol (1:1) and 
hexane / ethyl acetate (7:3) and then F4-NeuroPs was eluted with ethyl acetate/methanol (9:1). 
The eluate was dried under nitrogen and then derivatized in room temperature for 30 min with 
10% pentafluorobenzyl bromide and 10% N,N-diisopropylethylamine prepared in acetonitrile 
(2:1). Thereafter, it was dried under nitrogen and then derivatized with N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) + trimethylsilylchlorosilane (TMCS) 1% and 
N,N-dimethylformamide (2:1) (Sigma Aldrich, USA). After drying the reagents under 
nitrogen, samples were re-suspended in decane.  
Gas chromatography-mass spectrometry set at negative ion chemical ionization 
(TraceGC and DSQ II Mass Spectrometer, Thermo Fisher Scientific, MA USA) was used to 
determine 4(RS)-4-F4t-NeuroP [25]. Analytical column FactorFour™ (Varian, USA) fused 
silica capillary was used. Helium gas was the carrier gas and the column temperature was 
programmed from 140°C to 250°C at 30°C per minute then 250°C to 300°C at 4°C per minute 
and remained at this temperature for 10 minutes. The ion source temperature was 200°C and 
isobutane (1 mL/min) was used as the reagent gas for NICI. Selected ion monitoring was 
performed to monitor ions m/z 593.5 for 4(RS)-4-F4t-NeuroP and at m/z 583.5 for C21-15-F2t-
IsoP internal standard. Quantitation was achieved by relating the peak area of the 4(RS)-4-
F4t-NeuroP with C21-15-F2t-IsoP internal standard peak.  
 
Preparation of cardiomyocytes 
Cellular experiments were performed on freshly isolated left ventricular myocytes from the 
non-infarcted free wall (excluding the border zone). In brief, after cervical dislocation, the 
heart was removed, washed and aorta was cannulated to a modified Langendorff system. The 
heart was perfused by retrograde flow rate of 5–10 mL/min at 37°C for 6–8 min with a 
modified Tyrode solution composed of 113 mM NaCl, 4.7 mM, KCl, 0.6 mM KH2PO4, 0.6 
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mM Na2HPO4, 1.2 mM MgSO4, 12 mM NaHCO3, 10 mM KHCO3, 10 mM Hepes, (pH 7.4) 
and 0.1 g/mL liberase dispase (high research grade, Roche, France).  
After enzymatic treatment (4-6 min), a part of the left ventricle was removed and 
minced to separate the cells. Isolated myocytes were re-suspended in a sterile enzyme-free 
Tyrode solution, and the Ca2+ concentration of the ventricular cell suspension was gradually 
increased to 1 mM by the addition of CaCl2 in five sequential steps 100, 100, 300 and 500 µM 
with 10 min interval between steps. Finally the cardiomyocytes were kept at room 
temperature 22 – 24° C until use. Prior to the treatments, the freshly isolated cardiomyocytes 
were then superfused with standard Tyrode solution (121 mM NaCl, 5.0 mM KCl, 1.8 mM 
CaCl2, 0.5 mM MgCl2, 0.4 mM NaH2PO4, 24 mM NaHCO3, 0.1 mM EDTA and 5.5 mM 
glucose). Cardiomyocytes with obvious sarcolemmal blebs or spontaneous contractions were 
not used. Only cardiomyocytes with clear edges were selected and were used within 1-6 h 
after isolation.  
 
Inhibition of enzymatic lipid peroxidation of cardiomyocytes  
Inhibitors of enzymatic lipid peroxidation, anti-lipoxygenase (1 µM zileuton), anti-
cytochrome P450 (3 µM ketoconazole) and anti-cycloxygenase 2 (1 µM celecoxib) from 
Sigma-Aldrich, USA and anti-epoxide hydrolase (10 nM) from Cayman Chemicals USA, and 
a combination of 4 inhibitors were tested with and without 10 µM DHA + 1µM H2O2 in the 
cellular arrhythmias. We also used glutathione peroxidase enzyme, which reduce lipid 
peroxides to alcohols and H2O2. Stock solution of GPx was dissolved in water with 10 mM of 
phosphate sodium and 1 mM of dithiothreitol. GPx was either added before the mix DHA + 
H2O2 at concentration of 10 units (1 unit oxide 1 µM of DHA per minute) in Tyrode solution 
or after the DHA + H2O2 mix. For all the experiments, solutions were prepared freshly from 
the stock and diluted with Tyrode medium.  
 
Calcium channeling 
The effect of oxidation of -3 PUFAs on cell shortening and Ca2+ transients of field-
stimulated cardiomyocytes is monitored online using commercial myocyte calcium and 
contractility monitoring system (IonOptix®, Milton, MA, USA) connected to a standard 
inverted fluorescent microscope. Cells were field-stimulated with 1 ms current pulses 
delivered via two platinum electrodes. To monitor intracellular Ca2+ concentration, 
cardiomyocytes were loaded with the fluorescent ratiometric Ca2+ indicator Indo-1AM (2 µM, 
Invitrogen, France). They were simultaneously illuminated at 365 nm using a xenon arc bulb 
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light. Cytosolic Ca2+ concentration was determined by Indo-1 AM fluorescence which emit at 
405 nm and 480 nm concurrently. The ratio of 405nm/480nm indicates the cytosolic Ca2+ 
concentration. 
To observe arrhythmias (ventricular extrasystoles), the cells were bathed with 10 nM 
isoproterenol and stimulated with 30 s pacing period (1.0 Hz), followed by 30 s rest period 
[20,26]. Confocal imaging was performed using a Zeiss LSM510 confocal microscope (Carl 
Zeiss Inc., Oberkochen, Germany) equipped with an argon laser (488 nm) and a 60X, 1.3 NA 
oil immersion objective set at axial and radial resolutions of 1.0 and 0.4 µm, respectively. 
Ca2+ sparks were recorded in quiescent myocytes incubated with the Ca2+ indicator 
Fluo-4-AM (4 µM) (Molecular Probes, OR USA) for 15 min. The dye was excited at 488 nm 
and the fluorescence emission was collected through a 505 nm long-pass filter. Myocytes 
were field-stimulated at 1 Hz with 1 ms current pulses delivered via two platinum electrodes, 
one on each side of the perfusion chamber. During the rest period that follows stimulation, 
myocyte were repetitively scanned along the entire length of the cell at 1.5 ms intervals, for a 
maximum of 6 s. The laser intensity was reduced to 5% maximum to decrease cell damage 
and dye bleaching. Line scan diagrams were constructed by stacking emission lines, 
corresponding to excitation scans, in temporal order. An average of the Ca2+ sparks were 
determined by the intensity of each sequential scan line and plotting the mean intensity as a 
function of time. The SparkMaster® plugin for ImageJ® software was used to detect and 
analyze Ca2+ sparks. 
 
Immunoblot 
Proteins were extracted from basal left ventricular frozen cells (50 mg) homogenized with a 
manual polytron instrument. Cells were then lysed in 600 µL extraction buffer (Tris maleate 
10m M, NaF 35 mM, Triton 1%, activated orthovanadate 20 mM, inhibitor cocktail, Roche, 
France) for 45 min under rotated agitation. Membrane and cytosolic proteins were collected 
from the supernatant after 5 min centrifugation at 10, 000 x g at 4 °C. 
For the immunoprecipitation assay, left ventricular (LV) tissues were lysed in 1 mL 
buffer containing 10 mM Tris maleate (pH 6.8), 35 mM NaF, triton 1% and protease 
inhibitors (Roche 11873580001, France). A concentration of 10 µg anti-RyR2 antibody was 
used to immunoprecipitate RyR2 from 500 µg of LV homogenate. The samples were 
incubated with anti-RyR antibody in 0.5 ml modified RIPA buffer (Tris HCl 10 mM, pH 7.4, 
NaCl 150 mM, Triton 1%, NaF 5 mM and protease inhibitor cocktail) for 2 hours at 4°C. The 
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immune complexes were incubated with protein A/G magnetic beads (Pierce 88802, USA) at 
4°C for 2 hours, after which the beads were washed three times with RIPA buffer. 
To detect RyR2 protein oxidation, the immune complex was treated with 2,4 
dinitrophenylhydrazine (DNPH) and the DNP-derivatized protein samples formed were 
detected using on Immunoblot Protein oxidation detection Kit (Millipore S7150, USA). 
Proteins were then separated using SDS-PAGE, blotted onto nitrocellulose membranes (0.2 
µm, GE Healthcare, France) and incubated overnight at 4°C with primary antibodies: the type 
2 ryanodine receptor, RyR2 (1/1000 dilution, Pierce, France) and anti FKBP12.6 (1/1000 
dilution, RD System AF 4174, France). Protein levels were expressed relative to GAPDH 
(1/60000 dilution, AB8245, ABCAM, France). All immunoblots were developed and 
quantified using the Odyssey infrared imaging system (LI-COR Biosystems, USA) using 
infrared-labeled anti-mouse and anti-rabbit IgG (1/30000 dilution) secondary antibodies.  
 
Statistical analysis  
All data are given as mean ± SEM. Statistical analyses were performed using GraphPad 
Prism® (Prism 5 for Mac OS X). One-way ANOVA for multiple comparisons was used, 
followed by a parametric t-test with Fishers correction. For paired studies, Wilcoxon signed 
rank test is used. Percentage of arrhythmic cells data was analyzed by a χ2-test. A p-value of 
0.05 or less was indicated as statistically significant.  
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RESULTS  
 
DHA under oxidative stress conditions reduced cardiac arrhythmias  
 
AAP of DHA was evaluated in models of cardiac arrhythmias. Different conditions of 
oxidative status were obtained by preparing DHA solutions in the presence of an antioxidant, 
1 µM -tocopherol [27] or a pro-oxidant, 1 µM H2O2 [28]. Bathing isolated mice ventricular 
cardiomyocytes for 20 min in DHA prevented arrhythmias and concurs in part with previous 
report [11]. Importantly, AAP of DHA was potentiated by pro-oxidants and conversely 
prevented in the presence of -tocopherol (Figures 1A and 1B). When applied alone, H2O2 
and -tocopherol had no effect (Figure 1B), which further support the role of DHA oxidation 
on AAP. 
Additionally, we investigated the efficacy of DHA to reduce the trigger of ventricular 
extrasystoles (ES) in a post myocardial infarction (PMI) mice model established by coronary 
artery ligation and sensitized by norepinephrine (NE) [29]. PMI mice develop calcium 
dependent-ES due to increased diastolic calcium level in a context of increased ROS 
production [30]. These arrhythmias are potentiated by a norepinephrine challenge. In this 
validated model and as described in Table 1, intravenous injection of DHA to the mice 
reduced ES by 45%, which further reinforced the AAP of DHA in pro-oxidant conditions 
(Figures 1C and 1D).  
 
AAP are not mediated by enzymatic oxidation of DHA  
 
Enzymatic oxidation of DHA can develop endogenously [31], like the conditions used in this 
experimental approach. The AAP of DHA was investigated in cardiomyocytes in the presence 
of different inhibitors of enzymes that oxidize PUFAs namely cyclooxygenase (COX-2), 
lipooxygenase (LOX) and cytochrome P450 (CYP450). Individually or combined, the 
inhibitors did not modify the AAP of pro-oxidized DHA (Figure 2A). Our observation infers 
that DHA exert a strong AAP through non-enzymatic peroxidation process that generates 
metabolites such as F4-neuroprostanes and not through typical enzymatic process that 
involves for example resolvins, protectins and maresins. In order to further explore the 
chemical entities needed for the observed AAP, we buffered any hydroperoxyl derivatives 
potentially formed by our pro-oxidant condition (DHA+H2O2) by a late addition of 
glutathione peroxidase enzymes (GPx) (Figure 2B). AAP were still observed in these 
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conditions, indicating these effects are not related to endoperoxide or hydroperoxide 
metabolites of DHA. On the contrary, arrhythmia persisted when GPX was added prior to 
DHA+H2O2 indicating that H2O2 initiated the formation of the required metabolites of DHA 
for AAP (Figure 2B).  
 
Among the F4-neuroprostanes, 4(RS)-4-F4t-NeuroP had the most active AAP 
 
Supplementation of DHA to atherosclerotic LDLR-/- mice showed that liver F4-NeuroP 
concentration is negatively correlated to atherosclerosis risk [17]. The isomer 4(RS)-4-F4t-
NeuroP is the most abundant F4-NeuroPs formed from non-enzymatic DHA peroxidation 
[14]. In our in vitro experiments, incubation of DHA (10 µM) with H2O2 (1 µM) in Tyrode 
solution for 20 min generated 0.61±0.08 µM of 4(RS)-4-F4t-NeuroP (Figures 3A and B) 
whereas DHA with Vit E had no 4(RS)-4-F4t-NeuroP formed and DHA alone had trace 
amount (0.03±0.01 µM). Furthermore, we recently discovered that levels of 4(RS)-4-F4t-
NeuroP and another isomer, 10-F4t-neuroprostane (10-F4t-NeuroP) are concentrated in brains 
of preterm pigs [32], and in adult rat brain and heart [33]. 
From our findings, the high concentration of 4(RS)-4-F4t-NeuroP in the heart indicates 
a potential bioactive role. We compared the anti-arrhythmic effect of 4(RS)-4-F4t-NeuroP with 
other F4-neuroprostanes (10-F4t-NeuroP, 13-F4t-NeuroP, 14(RS)-4-F4t-NeuroP) (Table 2). Of 
the four F4-neuroprostanes tested, the 4(RS)-4F4t-NeuroP is the most potent (IC50100 nM) 
(Figure 3C).  
Despite the IC50100nM of 4(RS)-4-F4t-NeuroP, we subjected the maximum 
concentration (1 µM) to authenticate the AAP in our study. Our in vivo evaluation indicates 
AAP of 1 µM 4(RS)-4-F4t-NeuroP was comparable with the positive control 1 µM carvedilol, 
which is a referenced anti-arrhythmic drug (Figure 3D). Also, 4(RS)-4-F4t-NeuroP inhibited 
arrhythmias produced by the adenylyl cyclase activator, forskolin (Figure 3E) suggesting that 
-blocking properties is not involved in the AAP of 4(RS)-4-F4t-NeuroP. Absence of 
bradycardia following 4(RS)-4-F4t-NeuroP consolidates this hypothesis (Table 1). Further, the 
AAP of DHA+H2O2 and 4(RS)-4-F4t-NeuroP were similar suggesting that the AAP of DHA is 
largely due to the generation of 4(RS)-4-F4t-NeuroP in DHA+H2O2. 
 
4(RS)-4-F4t-NeuroP prevents RyR2 dysfunction 
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In our experimental models, the arrhythmias prevented by 4(RS)-4-F4t-NeuroP are mainly due 
to extrasystoles (ES). The mechanisms of triggering ES include alterations of Ca2+ 
homeostasis that are potentiated by catecholamines; the two phenomena observed after 
myocardial infarction [34]. The Ca2+ signaling alteration could be associated with a leaky type 
2 ryanodine receptor (RyR2) [35–37]. As a consequence, cytosolic Ca2+ levels in diastole rise 
and promote ES [38]. We thus evaluated the leaky behavior of RyR2 by measuring the 
frequency of spontaneous Ca2+ sparks by confocal microscopy [39] and the resting cytosolic 
Ca2+ concentration by epifluorescence. In our model, Ca2+ sparks events frequency was 
increased by isoprenaline (Figures 4A and 4B). This increase was partially prevented by DHA 
as also shown in previous reports [40,41]. Interestingly, the effects of DHA on Ca2+ sparks 
frequency were blunted by -tocopherol and enhanced by H2O2. PMI cardiomyocytes also 
exhibited an increased frequency of Ca2+ sparks that were significantly reduced by 4(RS)-4-
F4t-NeuroP. The changes in the sparks frequency followed changes in resting Ca2+ 
concentration (Figure 4C).  
At the molecular level, post-translational modifications of RyR2 may account for their 
leaky behavior [35–37].  We quantified RyR2 carbonylation, S-nitrosylation, phosphorylation 
and the degree of association of RyR2 with FKBP12.6 on the arrhythmic cardiomyocytes 
after 10 nM isoproterenol (ISO) treatment with or without 10 µM DHA, 10 µM DHA + 1 µM 
Vit E or 10 µM DHA + 1 µM H2O2 (Figure 5). Iso challenge promotes dissociation of 
FKBP12.6 from the RyR2 macromolecular complex as previously reported and accounts for 
the abnormal SR-Ca2+ leak [35] (Figure 5A). Iso also promotes RyR2 carbonylation, S-
nitrosylation and phosphorylation on serine 2808 (Figure 5B-D). These effects were 
prevented by DHA and more so by DHA + H2O2 compared to Iso and DHA + Vit E. This is 
supported by the lack of FKBP12.6 dissociation from the RyR2 complex of DHA or DHA + 
H2O2 treatment compared to Iso and DHA + Vit E (Figure 5A). Additionally, our 
observations indicate that oxidation of DHA is necessary to prevent RyR2 modification as no 
effect was found in the presence of Vit E, an antioxidant. In order to verify that the 
involvement of such an effect is due to a non-enzymatic oxidized lipid product of DHA, we 
repeated the evaluation on the arrhythmic cardiomyocytes with 4(RS)-4-F4t-NeuroP (Figure 
5A and 5B). The prevention of RyR2 phosphorylation and dissociation of FKBP12.6 of 
NeuroP was comparable to DHA + H2O2. This strongly supports that the effects of oxidized 
DHA and 4(RS)-4-F4t-NeuroP in correcting SR Ca2+ leak, normalizing diastolic Ca2+ level and 
preventing ES triggering results from the counteraction of RyR2 post-translational 
modifications and RyR2 dysfunction. 
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DISCUSSION 
 
In the present study, we clearly demonstrated that oxidized DHA possesses potent AAP in 
cellulo and in vivo, and that unmodified DHA per se was inactive. This effect is not mediated 
by enzymatic lipid peroxidation but instead by neuroprostanes, the stable end products of the 
non-enzymatic lipid peroxidation of DHA, particularly 4(RS)-4-F4t-NeuroP. This metabolite 
displayed a unique and unprecedented mode of action in the family of lipid mediators and of 
any known endogenous biomolecule, as it stabilized RyR2 and maintained this complex 
closed during diastole. 
This discovery bridges the missing relationship between cardiac ischemic events and 
the AAP of DHA. Indeed, following cardiac ischemic diseases and myocardial infarction 
there is a burst of ROS [42] that can be involved in the generation of the arrhythmias, the 
origin of SCD [43]. Such an abrupt imbalance of the oxidative status can oxidize proteins 
[44], nucleic acids [45] and lipids [46]. These highly reactive compounds play a pivotal role 
in the pathogenesis of post-ischemic injury that progresses to SCD [47,48]. Classically, there 
is a consensus that overproduction of ROS are mainly deleterious and do not play a role in 
normal physiology. For example it has been shown that an isoketal, E2-IsoK, originating from 
the oxidation of arachidonic acid can produce adducts with the sodium channel protein 
NaV1.5, perturbing its activity in a pro-arrhythmic way [47]. However, the possibility that 
non-enzymatic oxygenated metabolites of 3 PUFAs can exert counter effects has been under 
investigated.  
We have previously reported that DHA needs to be oxidized to influence ionic channel 
activities [12] and it is agreed by others that such effects on ionic channels contributes to the 
AAP of DHA [49]. We hereby demonstrated that the AAP of DHA are dependent on the 
oxidative status of the environment, and that non-enzymatic auto-oxidation of DHA was a 
perquisite to AAP. Our assays pinpointed neuroprostane metabolites as the potential 
metabolites with APP properties. The main isomer, 4(RS)-4-F4t-NeuroP, showed potent AAP 
in cellulo in a dose dependent manner and also in vivo in PMI mice. 
At the cellular level, the mechanism of action is unlikely to be due to a -blocker 
effect, but the AAP can instead be explained by a rycal-like effect, in particular, stabilization 
of the RyR2 complex with FKBP12.6 [50]. This effect was strongly supported by both 
oxidized DHA and 4(RS)-4-F4t-NeuroP in correcting SR Ca2+ leak, normalizing diastolic Ca2+ 
levels and from the prevention of the dissociation of FKBP12.6 from RyR2. Although we can 
not exclude a direct effect of 4(RS)-4-F4t-NeuroP on RyR2, in contrast to rycal effects, we 
 15
also observed that both oxidized DHA and 4(RS)-4-F4t-NeuroP prevent RyR2 hyperactive S-
nitrosylation, oxidation and phosphorylation, suggesting an upstream mechanism rather than a 
direct effect on RyR2 as previously reported [37]. Altogether we showed that 4(RS)-4-F4t-
NeuroP is capable of preventing ES triggering effects from the prevention of RyR2 post-
translational modifications and RyR2 dysfunction by normalizing RyR2 activity in diastole 
and thus calcium homeostasis. 
Emulsion of 3 PUFAs, injected intravenously has been shown to be anti-arrhythmic 
in a canine model of myocardial infarction [7] and similar effects on sustained ventricular 
tachycardia have been observed in humans [20,51]. The use of an in vivo ischemic model to 
monitor the triggering of ventricular ES clearly confirmed our hypothesis that DHA auto-
oxidatively has to be transformed into neuroprostane for rapid inhibition of arrhythmias.  
The pre-requisite for DHA oxidation to elicit any AAP could explain the lack of 
elucidation for the beneficial effects of 3 PUFAs other than in ischemic cardiovascular 
diseases [2,52,53]. After initial reports establishing that 3 PUFAs have cardioprotective 
properties, the beneficial effects were then extended to many if not all cardiovascular 
problems, even those that are not ischemic [53,54]. This mindset could be the drawback for 
the proper development of therapeutic targets in cardiac ischemia and for the difficulty in 
justifying its valuable impact in cardioprotection. Overall, the mechanism of action we 
describe here can explain the favorable impact of 3 PUFAs in chronic diseases implicating 
RyR2 dysfunction when an unbalanced oxidative status is present.  
 
CONCLUSION 
 
From this work, we conclude that the oxidation of DHA to 4(RS)-4-F4t-NeuroP is 
necessary to prevent ischemia-induced arrhythmias. We propose that in oxidative stress 
conditions such as ischemic diseases, non-enzymatic oxygenated metabolites of DHA formed 
by peroxidation of cardiac membrane lipids, notably 4(RS)-4-F4t-NeuroP, are responsible for 
the AAP of DHA by countering the cellular stress by ROS. Importantly, it appears that non-
enzymatically oxygenated metabolites of 3 PUFAs can communicate and exert a 
physiological role. This highlights potential beneficial effects of increased ROS production 
dependent on the cellular environment.  
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F4-neuroprostanes Structure Percentage of reduced arrhythmias 
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Table 2. Antiarrhythmic properties of different F4-neuroprostanes on single cardiac ventricular 
myocytes. Cardiomyocytes were incubated for 20 minutes in the presence of 1µM F4-
neuroprostanes prior using the pro-arrhythmic protocol (see Materiel & Methods). Each 
compound was tested on 30 cells approximately (4-5 mice). Results are expressed in 
percentage as the reduction of the number of arrhythmic cells after the treatment relative to 
control (no treatment). 
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Highlights: 
 
- Oxidation of DHA (oxDHA) is a pre-requisite condition for anti-arrhythmic effect. 
- 4(RS)-4-F4t-neuroprostane from oxDHA displayed potent anti-arrhythmic properties. 
- Anti-arrhythmia effect involves stabilization of the FKPB12.6/RyR2 complex. 
- Non-enzymatic metabolites of omega-3 fatty acids have physiological roles. 
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TABLE
SHAM PMI
(n = 6) (n =9)
HR (bpm) 427 ± 29 454 ± 37
EF (%) 60 ± 4 25 ± 12 ***
FS (%) 32 ± 3 12 ± 6 ***
FAC (%) 52 ± 3 19 ± 9 ***
EF (%) B-mode 58 ± 5 12 ± 7 ***
Ao VTI (mm) 49.0 ± 5.8 35.6 ± 4.0 ***
Table 1. Echocardiographic parameters in sham and infarcted mice. HR, heart rate; EF, 
ejection fraction; FS, fractional shortening; FAC, fractional area change; AoVTI, aortic 
velocity time integral. Data are represented as mean ± SD. *** p<0.001 for SHAM vs. PMI. 
